Feanalytic has received major funding and support from Novo Nordisk Foundation, Business Finland, and SPARK Finland. We are a part of the InFLAMES Research Flagship. Through these partnerships, Feanalytic aims to expedite the integration of its technology toward clinical practice, revolutionizing the diagnosis and treatment of IBD worldwide.
Novel diagnostic method to detect and monitor Inflammatory Bowel Disease
Gut diseases are common and many suffer from abdominal symptoms including pain and altered stool
Often the cause of gut symptoms remains unidentified. Feanalytic develops a new quick and non-invasive diagnostic assay to detect and monitor Inflammatory bowel disease (IBD) and its subtypes. The new diagnostic tool will improve IBD diagnosis and personal treatment.
Our method is based on detection of keratin biomarkers from stool samples. The patented method enables patient-friendly diagnosis of IBD disease and its specific subtypes. Improved noninvasive IBD diagnostics will benefit both patients and healthcare providers.
News
Our Partners
